Now speaking at Global Voices in Renal Oncology (VIRO) organized by OncoDaily, Dr. Maryam Soleimani, Clinical Assistant Professor at the Division of Medical Oncology of University of British Columbia, delivered a talk on “VHL and Kidney Cancer: the Role of Specialized VHL Clinic”.
She highlighted the complexity and importance of managing Von Hippel-Lindau (VHL) disease, an inherited cancer syndrome that can affect multiple organs and presents differently even within the same family. Dr. Soleimani emphasized the transformative impact of Belzutifan, approved in 2021, which targets the VHL pathway and has shown a 70% response rate in renal tumors, significantly reducing the need for repeated surgeries while requiring careful multidisciplinary management.
She also stressed the critical role of specialized VHL clinics, which provide coordinated, holistic care—including genetic counseling and organ-specific management—and improve guideline adherence, early detection, and patient outcomes. By supporting collaboration among specialists, offering longitudinal follow-up, and integrating patient priorities, these clinics not only enhance the patient experience but also drive research innovation and advance the field of rare-disease oncology.
Join us in the conversation.